Clinical Trial Update: Tolerability and Steady-state Pharmacokinetics of BIA 6-512 [Phase 1]

View source ↗

Summary

Phase 1 study reports tolerability and steady-state pharmacokinetics of BIA 6-512 in Parkinson disease; trial completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• BIA 6-512

Snippet

Sponsor: Bial - Portela C S.A. | Conditions: Parkinson Disease | Phase 1 | Status: COMPLETED